Anna Eramo
CIK: 0002030921
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LB PHARMACEUTICALS INC
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Sep 10, 2025LBRX
LB PHARMACEUTICALS INC
Disposition(D)DirectEmployee Stock Option (Right to Buy)
26.9K shares- - Sep 10, 2025LBRX
LB PHARMACEUTICALS INC
Award(A)DirectEmployee Stock Option (Right to Buy)
26.9K shares- - Sep 10, 2025LBRX
LB PHARMACEUTICALS INC
Disposition(D)DirectEmployee Stock Option (Right to Buy)
6.3K shares- - Sep 10, 2025LBRX
LB PHARMACEUTICALS INC
Award(A)DirectEmployee Stock Option (Right to Buy)
6.3K shares- - Sep 10, 2025LBRX
LB PHARMACEUTICALS INC
Award(A)DirectEmployee Stock Option (Right to Buy)
155.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 10, 2025 | LBRX LB PHARMACEUTICALS INC | Disposition(D) Employee Stock Option (Right to Buy) | 26,893 | - | - | Direct |
| Sep 10, 2025 | LBRX LB PHARMACEUTICALS INC | Award(A) Employee Stock Option (Right to Buy) | 26,893 | - | - | Direct |
| Sep 10, 2025 | LBRX LB PHARMACEUTICALS INC | Disposition(D) Employee Stock Option (Right to Buy) | 6,275 | - | - | Direct |
| Sep 10, 2025 | LBRX LB PHARMACEUTICALS INC | Award(A) Employee Stock Option (Right to Buy) | 6,275 | - | - | Direct |
| Sep 10, 2025 | LBRX LB PHARMACEUTICALS INC | Award(A) Employee Stock Option (Right to Buy) | 155,812 | - | - | Direct |
1-5 of 5 transactions
About Eramo Anna
Eramo Anna (SEC CIK 0002030921) files insider reports with the SEC as Chief Medical Officer of LB PHARMACEUTICALS INC (LBRX).
Signal8 holds 2 ownership filings by Eramo Anna (1 Form 3, 1 Form 4), filed between Sep 10, 2025 and Sep 12, 2025. Those filings report 5 transactions, the latest on Sep 10, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Eramo Anna's filings is in NEW YORK, NY.
Recent filings by Eramo Anna
- Sep 10, 2025: Disposition to issuer transaction of LBRX derivative securities (Form 4, code D).
- Sep 10, 2025: Grant or award of LBRX derivative securities (Form 4, code A).
- Sep 10, 2025: Disposition to issuer transaction of LBRX derivative securities (Form 4, code D).
- Sep 10, 2025: Grants or awards of LBRX derivative securities (2 lines, Form 4, code A).
Other insiders filing for LB PHARMACEUTICALS INC (LBRX)
- Miller Joseph M, Chief Financial Officer
- Kozauer Susan Gani, Chief Medical Officer
- Deep Track Biotechnology Master Fund, Ltd., 10% Owner
- RUFFOLO ROBERT R, Director
- Nussbaum Ran, Director
- Luse Rebecca, Director